Find Paid Clinical Trials in Cleveland, Ohio

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... Ohio » ... Cleveland

WalkAide Compared to Ankle-Foot Orthosis (AFO) in Stroke Patients

Condition: Stroke
Interventions: Device: WalkAide; Other: Ankle-Foot Orthosis (AFO)
Sponsor: Innovative Neurotronics
Not yet recruiting - verified March 2010
Radiosurgery, Bevacizumab, and Irinotecan Hydrochloride in Treating Patients With Recurrent Glioblastoma

Conditions: Glioblastoma; Gliosarcoma; Brain Tumor
Interventions: Radiation: radiosurgery; Biological: bevacizumab; Drug: irinotecan hydrochloride
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified March 2010
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?

Condition: Workplace Migraine Treatment
Interventions: Drug: Usual prescribed triptan; Drug: Treximet for migraine treatment
Sponsors: The Cleveland Clinic; GlaxoSmithKline
Recruiting - verified September 2009
Peripartum Cardiomyopathy

Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Heart Biomarker Evaluation in Apnea Treatment

Conditions: Cardiovascular Disease; Obstructive Sleep Apnea; Coronary Artery Disease
Interventions: Other: Healthy Lifestyles and Sleep Education plus PAP; Other: Healthy Lifestyles and Sleep Education plus Supplemental Oxygen; Other: Healthy Lifestyles and Sleep Education
Sponsors: University Hospitals of Cleveland; Case Western Reserve University; Partners HealthCare; Johns Hopkins University; VA Boston Healthcare System
Recruiting - verified March 2010
PeriOperative ISchemic Evaluation-2 Trial

Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsor: Hamilton Health Sciences
Not yet recruiting - verified March 2010
Oxygen Saturation Alarms in the Neonatal Intensive Care Unit

Condition: Hypoxemia
Intervention:
Sponsor: Covidien
Recruiting - verified March 2010
Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes

Condition: Type 1 Diabetes Mellitus
Interventions: Behavioral: Diabetes related psychological counseling and education; Device: Continuous Glucose Monitor
Sponsors: University Hospital Case Medical Center; National Institute of Mental Health (NIMH)
Not yet recruiting - verified March 2010
Temsirolimus and Bevacizumab in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Condition: Prostate Cancer
Interventions: Drug: temsirolimus; Biological: bevacizumab; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; The Cleveland Clinic; Ireland Cancer Center
Recruiting - verified March 2010
The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras

Condition: Migraine
Intervention:
Sponsors: The Cleveland Clinic; Baaken Heart Brain Institute
Recruiting - verified March 2010
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

Conditions: Fallopian Tube Cancer; Ovarian Sarcoma; Ovarian Stromal Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Uterine Sarcoma; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IV Endometrial Carcinoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Uterine Sarcoma; Stage IV Vulvar Cancer; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer
Interventions: Radiation: stereotactic radiosurgery; Procedure: quality-of-life assessment
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified March 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Azilsartan Medoxomil Study in Hypertensive Children

Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

Condition: Fibromyalgia
Interventions: Drug: Placebo; Drug: Milnacipran
Sponsors: Forest Laboratories; Cypress Bioscience, Inc.
Recruiting - verified February 2010
nEw3 Post-approval Study

Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
4968 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
4965 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome

Condition: Chronic Pain
Intervention: Device: Deep Brain Stimulation for Thalamic Pain Syndrome
Sponsors: The Cleveland Clinic; National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (info added by University of Michigan Data Coordinating Center)
Recruiting - verified November 2009
Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

Condition: Ischemia
Intervention: Drug: ambrisentan
Sponsors: The Cleveland Clinic; Gilead Sciences
Recruiting - verified February 2010
Trial of Percutaneous Endovascular Aneurysm Repair (PEVAR)

Condition: Abdominal Aortic Aneurysm
Interventions: Device: PEVAR (ProGlide closure); Device: SEVAR (IntuiTrak); Device: PEVAR (Prostar XL closure)
Sponsors: Endologix; Abbott Vascular
Not yet recruiting - verified February 2010
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: ASP1941; Drug: Metformin; Drug: Placebo
Sponsor: Astellas Pharma Inc
Recruiting - verified March 2010
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010
Treatment Interruption of Natalizumab

Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Not yet recruiting - verified February 2010
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Not yet recruiting - verified March 2010
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01; Drug: Normal Saline
Sponsor: Alnylam Pharmaceuticals
Recruiting - verified March 2010
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Dopamine in Acute Decompensated Heart Failure II

Condition: Acute Decompensated Heart Failure
Interventions: Drug: High-dose furosemide; Drug: Low-dose furosemide; Drug: Low-dose furosemide combined with low-dose dopamine
Sponsor: Larissa University Hospital
Recruiting - verified January 2010
Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) Patients

Condition: Gait Disturbance in Multiple Sclerosis Patients
Interventions: Other: Rhythmic auditory stimulation; Other: Walking exercise
Sponsors: The Cleveland Clinic; National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone

Conditions: Fecal Incontinence; Anal Incontinence
Interventions: Device: Biodesign Tissue Repair Graft; Other: Control
Sponsor: Cook
Recruiting - verified March 2010
To Assess the Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe, Stable COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults

Conditions: Aging; Alzheimer's Disease
Interventions: Other: Exercise Training; Other: Cognitive Training; Other: Flexibility Training; Other: Educational Sessions
Sponsors: The Cleveland Clinic; National Institutes of Health (NIH)
Recruiting - verified February 2009
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial to Evaluate the Efficacy and Safety of a New Formulation of Kogenate for Hemophilia A

Conditions: Blood Coagulation Disorders; Hemophilia A
Interventions: Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973)
Sponsor: Bayer
Recruiting - verified March 2010
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

Conditions: Staphylococcal Skin Infections; Streptococcal Infections
Intervention: Drug: Ceftobiprole
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
Sponsor: Novartis
Recruiting - verified March 2010
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Gram-positive Infections

Condition: Gram Positive Bacterial Infection
Intervention: Drug: Daptomycin
Sponsor: Cubist Pharmaceuticals
Recruiting - verified February 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

Condition: Dry Eye Disease
Interventions: Drug: Azithromycin Ophthalmic Solution, 1%; Drug: Placebo
Sponsor: Inspire Pharmaceuticals
Recruiting - verified February 2010
AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: MEK inhibitor AZD6244; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875 6.25 mg; Drug: TAK-875 25 mg; Drug: TAK-875 50 mg; Drug: TAK-875 100 mg; Drug: TAK-875 200 mg; Drug: Glimepiride 2 mg or 4mg; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Condition: Abdominal Pain Upper
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified February 2010
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma

Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Conditions: Graft-Versus-Host Disease; Immune System Disorders
Interventions: Drug: Mycophenolate Mofetil; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
High-Dose Methotrexate and Liposomal Cytarabine in Treating Patients With Central Nervous System (CNS) Metastases From Breast Cancer

Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection

Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Telephone Support to Improve Adherence to Anti-HIV Medications

Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Neural Prostheses and Gait Performance: Model-Based Strategies

Condition: Hemiplegia
Intervention: Device: EMS 2000
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

Condition: Human Papillomavirus Infection
Interventions: Biological: V503; Biological: Comparator: Menactra™ (Concomitant); Biological: Comparator: Adacel™ (concomitant); Biological: Comparator: Menactra™ (Non-Concomitant); Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor: Merck
Recruiting - verified March 2010
Vaccine Therapy in Treating Women With Triple-Negative Breast Cancer

Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified February 2010
Effect of Succinylcholine on Patients Using Statins

Condition: Pain
Intervention: Drug: Succinylcholine
Sponsor: Outcomes Research Consortium
Recruiting - verified March 2010
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Subjects With Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Lenalidomide (CC-5013) in combination with sunitinib
Sponsor: Celgene Corporation
Recruiting - verified February 2010
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Condition: Paroxysmal Atrial Fibrillation
Interventions: Procedure: Atrial Fibrillation ablation procedure; Device: NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL
Sponsor: Biosense Webster, Inc.
Recruiting - verified February 2010
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy

Conditions: Inflammation; Obesity; Pregnancy; Fetal Growth
Intervention: Dietary Supplement: Omega-3 Fish Oil
Sponsors: MetroHealth Medical Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma

Condition: Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC; Drug: AZD1152 + LDAC
Sponsor: AstraZeneca
Recruiting - verified March 2010
Radiation Therapy in Treating Patients With Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: intracavitary balloon brachytherapy; Radiation: intraoperative radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Conditions: Cervical Cancer; Therapy-related Toxicity; Vaginal Cancer
Interventions: Drug: cisplatin; Drug: triapine; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: computed tomography; Procedure: quality-of-life assessment; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clazosentan in Aneurysmal Subarachnoid Hemorrhage

Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Clazosentan; Drug: Clazosentan; Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
Daily Wear Corneal Infiltrative Event Study

Conditions: Myopia; Hyperopia; Corneal Infiltrative Events
Intervention: Device: lotrafilcon A contact lenses
Sponsors: University Hospital Case Medical Center; Alcon Laboratories
Recruiting - verified January 2010
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Condition: Schizophrenia
Interventions: Drug: oral risperidone; Drug: paliperidone palmitate
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Condition: Hypertension
Interventions: Drug: Telmisartan 80mg; Drug: Telmisartan80mg/hydrochlorothiazide25mg; Drug: Telmisartan80mg/hydrochlorothiazide25mg; Drug: Telmisartan
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC (low dose cytosine arabinoside)
Sponsor: AstraZeneca
Recruiting - verified March 2010
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Ablation Versus Anti-Arrhythmic (AA) Drug Therapy for AF - Pivotal Trial

Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: ACT-064992 (macitentan); Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
28 Day Repeat Dose in Cystic Fibrosis Patients

Condition: Cystic Fibrosis
Interventions: Drug: SB656933; Drug: Placebo; Drug: SB656933
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.

Condition: Alzheimer Disease
Intervention: Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methoxyamine; Drug: temozolomide; Genetic: DNA analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas

Conditions: Pancreatic Fistula; Distal Pancreatectomy Complications; Falciform Patch Pancreatic Closure; Fibrin Glue Pancreatic Closure
Interventions: Procedure: Falciform patch and fibrin glue application; Procedure: standard pancreatic closure
Sponsor: Thomas Jefferson University
Recruiting - verified February 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)

Condition: Pulmonary Hypertension
Intervention: Drug: UT-15C
Sponsor: United Therapeutics
Recruiting - verified February 2010
Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)

Condition: Coronary Artery Chronic Total Occlusion
Intervention: Device: Recanalization of a coronary chronic total occlusion
Sponsor: BridgePoint Medical
Recruiting - verified March 2010
Effects of Pregabalin (Lyrica) on Sleep Maintenance in Subjects With Fibromyalgia

Conditions: Fibromyalgia; Sleep Disorders
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Condition: Herpes Labialis
Intervention: Drug: Famciclovir
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Tanezumab in Adults With Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Condition: Bipolar I, Depression
Intervention: Drug: lurasidone
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Conditions: Bipolar; Depression
Interventions: Drug: lurasidone; Drug: lurasidone; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Condition: Bipolar Depression
Interventions: Drug: lurasidone + (lithium or divalproex); Drug: Placebo + (lithium or divalproex)
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Condition: Behcet Syndrome
Interventions: Drug: Apremilast (CC-10004); Drug: Placebo
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Pain Therapy in HIV Neuropathy

Conditions: HIV Infections; Peripheral Neuropathy
Interventions: Drug: Duloxetine; Drug: Duloxetine placebo; Drug: Methadone; Drug: Methadone placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Condition: Carcinoma, Non-Small Cell Lung
Interventions: Biological: REOLYSIN®; Drug: Carboplatin; Drug: Paclitaxel
Sponsor: Oncolytics Biotech
Recruiting - verified March 2010
First Line Hepato Cellular Carcinoma (HCC)

Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and Safety Study Dosing of Rabeprazole in New Borns With Gastroesophageal Reflux Disease (GERD).

Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Conditions: HIV Infections; Treatment Naive
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: MetMAb; Drug: placebo
Sponsor: Genentech
Recruiting - verified March 2010
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Conditions: Overactive Bladder; Neurogenic Detrusor Overactivity
Intervention: Drug: Fesoterodine
Sponsor: Pfizer
Recruiting - verified March 2010
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Open-Label Study of Oral Treprostinil in Digital Ulcers

Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Efficacy and Safety of TAK-491 Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Efficacy and Safety of Azilsartan Plus Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery

Conditions: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer
Interventions: Drug: topotecan hydrochloride; Other: pharmacological study
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: Cetuximab; Drug: Irinotecan; Biological: IMC-A12
Sponsors: ImClone LLC; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified February 2010
Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: idarubicin; Drug: pravastatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Safety of Urate Elevation in Parkinson's Disease

Condition: Parkinson Disease
Interventions: Drug: Placebo; Drug: inosine; Drug: inosine
Sponsors: The Parkinson Study Group; Massachusetts General Hospital; Harvard School of Public Health; University of Rochester; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified March 2010
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

Condition: Ischemia
Interventions: Other: BMS747158; Other: BMS747158
Sponsor: Lantheus Medical Imaging
Recruiting - verified March 2010
Comparison Between the Fastrach and CTrach Laryngeal Mask Airway

Condition: Intubation
Interventions: Device: Fastrach Laryngeal Mask; Device: CTrach Laryngeal Mask
Sponsor: Outcomes Research Consortium
Recruiting - verified March 2010
Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome.

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Rollover Protocol for Prior SU011248 Protocols

Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Open-label Study Providing Monotherapy (Sitaxsentan) and Combination Therapy (Sitaxsentan+Sildenafil) to Subjects With PAH to Assess Long-term Safety

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Sitagliptin Cardiovascular Outcome Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified March 2010
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Cancer; Solid Tumors
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Condition: Lymphoproliferative Disorders
Interventions: Drug: ABT-263; Drug: rituximab
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: BIW-8962
Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified January 2009
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy

Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
NINDS CRC Chronic Migraine Treatment Trial

Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Viral Shedding of MEDI-559 in Healthy 1 to <24 Month-Old Children

Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Condition: Diabetic Macular Edema
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Condition: Acromegaly
Interventions: Drug: Octreotide Implant; Drug: Sandostatin LAR Depot
Sponsor: Endo Pharmaceuticals Solutions Inc.
Recruiting - verified February 2010
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsor: Pfizer
Recruiting - verified March 2010
Imaging Procedure Using ALA in Finding Residual Tumor in Patients With Grade IV Malignant Astrocytoma Who Are Undergoing Surgery

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: aminolevulinic acid
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Condition: Ovarian Cancer
Intervention: Biological: bevacizumab
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Condition: GERD
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Renal Insufficiency After the Administration of Magnevist

Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified March 2010
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Vandetanib, Oxaliplatin, and Docetaxel in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: docetaxel; Drug: oxaliplatin; Drug: vandetanib; Other: placebo
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects
Interventions: Drug: temozolomide; Drug: vorinostat; Procedure: adjuvant therapy; Procedure: cognitive assessment; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2010
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB Rectal Cancer

Condition: Colorectal Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic laparoscopic surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Condition: Head and Neck Cancer
Interventions: Drug: docetaxel; Drug: erlotinib hydrochloride; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase 1 Dose Escalation Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Condition: Age-Related Macular Degeneration
Intervention: Drug: PF-04523655
Sponsors: Pfizer; Quark Pharmaceuticals
Recruiting - verified March 2010
Fibromyalgia Health Outcome Study on Cost of Treatments

Condition: Fibromyalgia
Intervention: Drug: Treatment for Fibromyalgia
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Chemotherapy and Radiation Therapy With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: vandetanib; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsor: Cangene Corporation
Recruiting - verified March 2010
TODAY Genetics Study

Condition: Type 2 Diabetes
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
An Extension Study of Tocilizumab in Patients Completing Treatment in Tocilizumab Core Studies

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: Standard anti-rheumatic treatment
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, or Osteosarcoma

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
ADO II Clinical Study

Condition: Patent Ductus Arteriosus
Intervention: Device: AMPLATZER Duct Occluder II
Sponsor: AGA Medical Corporation
Recruiting - verified March 2010
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: placebo
Sponsors: Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010
Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years)With Skin and Skin Structure Infections

Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor: Cubist Pharmaceuticals
Recruiting - verified February 2010
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Evaluation of a Medical Food for Chronic Wounds

Condition: Foot Ulcer, Diabetic
Interventions: Other: Medical Food; Other: Drink mix calorically similar to experimental product
Sponsor: Abbott Nutrition
Recruiting - verified March 2010
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: nsNSAIDs
Sponsor: Pfizer
Recruiting - verified March 2010
Regional Anesthesia in Colon Rectal Surgery

Condition: Colon Cancer
Interventions: Procedure: bupivacaine and fentanyl; Drug: sevoflurane
Sponsor: Outcomes Research Consortium
Recruiting - verified March 2010
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Pazopanib in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Conditions: Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Pemetrexed Disodium With or Without Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Responded to Previous Erlotinib

Condition: Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: pemetrexed disodium
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
Sponsors: M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2010
Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study

Condition: Atrial Septal Defect
Intervention: Device: AMPLATZER Septal Occluder
Sponsor: AGA Medical Corporation
Recruiting - verified January 2009
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People With Idiopathic Pulmonary Fibrosis

Condition: Pulmonary Fibrosis
Interventions: Drug: Prednisone; Drug: Azathioprine; Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study

Condition: Ventricular Septal Defects
Intervention: Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
Sponsor: AGA Medical Corporation
Recruiting - verified October 2009
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Condition: Coronary Heart Disease
Interventions: Drug: dalceptrapib; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2009
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Transthyretin-Associated Amyloidoses Outcomes Survey (THAOS)

Condition: TTR-associated Amyloidosis
Intervention: Other: THAOS is a noninterventional patient registry
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Study of Ambrisentan and Phosphodiesterase Type-5 Inhibitor (PDE-5i) to Treat Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ambrisentan plus sildenafil or tadalafil
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment. (SPINART)

Condition: Hemophilia A
Interventions: Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS); Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS)
Sponsor: Bayer
Recruiting - verified March 2010
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
The Vascutek AnacondaTM Stent Graft System Phase II IDE Study

Condition: Infrarenal Abdominal Aortic Aneurysm
Intervention: Device: Anaconda Stent Graft System
Sponsors: Terumo CVS; Vascutek Ltd., Scotland
Recruiting - verified March 2010
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

Condition: Epilepsy
Intervention: Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
The Study of Barrett's Esophagus: What Are the Factors of Progression

Conditions: Barrett's Esophagus; Esophageal Neoplasms
Intervention:
Sponsors: Kansas City Veteran Affairs Medical Center; TAP Pharmaceutical Products Inc.
Recruiting - verified February 2010
Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

Condition: Rheumatoid Arthritis
Interventions: Drug: Liquid Certolizumab pegol; Drug: Liquid Certolizumab pegol; Other: Placebo; Drug: Methotrexate
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety Study of TAK-700 in Subjects With Prostate Cancer.

Condition: Prostatic Neoplasms
Intervention: Drug: TAK-700
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
VA NEPHRON-D: Diabetes iN Nephropathy Study

Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Conditions: Breast Cancer; Carcinoma of the Breast
Interventions: Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech
Recruiting - verified March 2010
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Intervention: Drug: asparaginase-Erwinia
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA•CER) (Study P04736AM2)

Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified March 2010
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer

Condition: Metastatic Brain Cancer
Intervention: Drug: GLIADEL
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

Condition: Epilepsies, Partial
Interventions: Drug: pregabalin 600 mg/day; Drug: pregabalin 150 mg/day
Sponsor: Pfizer
Recruiting - verified March 2010
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Adult Double Cord Blood Transplant Study

Conditions: Cord Blood Stem Cell Transplantation; Hematologic Malignancies
Intervention: Procedure: Cord blood transplantation
Sponsor: Center for International Blood and Marrow Transplant Research
Recruiting - verified March 2010
Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone

Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: thoracoscopic surgery; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Conditions: Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat; Other: pharmacological study
Sponsors: University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified July 2009
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

Condition: Melanoma
Intervention: Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Available - verified March 2010
Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179)

Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Conditions: Schizophrenia; Schizophrenic Disorders; Psychotic Disorders; Dementia Praecox.
Intervention: Drug: Paliperidone ER
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: CC-4047
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: dasatinib; Other: laboratory biomarker analysis; Other: physiologic testing
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Condition: Heart Decompensation
Interventions: Drug: Placebo; Drug: Nesiritide
Sponsor: Scios, Inc.
Recruiting - verified February 2010
Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Conditions: Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Radiosurgery in Treating Patients With Kidney Tumors

Condition: Kidney Cancer
Intervention: Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: levonorgestrel; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors

Condition: Kidney Cancer
Interventions: Procedure: conventional surgery; Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Condition: Thoracic Aortic Aneurysms
Intervention: Device: Relay Thoracic Stent-Graft
Sponsor: Bolton Medical
Recruiting - verified March 2010
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease

Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsor: Amgen
Recruiting - verified March 2010
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Combination Therapy in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: bosentan; Drug: bosentan and sildenafil combination
Sponsor: Actelion
Recruiting - verified February 2010
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate; Drug: octreotide acetate; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Procedure: computed tomography
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Expanded Access Program for Maraviroc At Multiple Centers

Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI - Panitumumab; Drug: FOLFIRI - Bevacizumab
Sponsor: Amgen
Recruiting - verified February 2010
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

Conditions: Leukemia; Long-term Effects Secondary to Cancer Therapy in Adults; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Sexual Dysfunction and Infertility; Sexuality and Reproductive Issues; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Procedure: fertility assessment and management; Procedure: management of therapy complications; Procedure: ultrasound imaging
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

Condition: Influenza
Intervention: Drug: oseltamivir (Tamiflu®)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.

Condition: Lupus Nephritis
Interventions: Drug: mycophenolate mofetil [CellCept]; Drug: Cyclophosphamide; Drug: mycophenolate mofetil [CellCept]; Drug: Azathioprine
Sponsors: Hoffmann-La Roche; Aspreva Pharmaceuticals
Recruiting - verified February 2010
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab; Drug: sunitinib malate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
VEGF Trap in Treating Patients With Metastatic or Unresectable Kidney Cancer

Condition: Kidney Cancer
Intervention: Biological: aflibercept
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Visual Field Assessment With Subjects Who Receive Either Lyrica Or Sugar Pills

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Intervention: Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
EXTEND (Eltrombopag Extended Dosing Study)

Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified March 2010
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery

Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets; Other: Placebo
Sponsor: United Therapeutics
Recruiting - verified March 2010
A Study on the Effectiveness and Safety of Diazepam Injection (Vanquix™) for Patients With Epilepsy That Receive Antiepileptic Drugs, But Still Experience Acute Repetitive Seizures (Bouts or Clusters of Seizures) That Require Treatment

Conditions: Epilepsy; Epilepsy, Generalized; Epilepsy, Complex Partial; Epilepsies, Partial; Seizures
Interventions: Drug: Diazepam; Drug: Placebo
Sponsor: King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.

Condition: Antithrombin III Deficiency
Intervention: Drug: Plasma-derived AT-III concentrate
Sponsor: Grifols Biologicals Inc.
Recruiting - verified March 2010
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Genetic: protein expression analysis; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2); Osteoporosis; Ovarian Cancer
Interventions: Drug: zoledronic acid; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: bosentan; Drug: placebo
Sponsor: Actelion
Recruiting - verified March 2010
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsor: EDAP TMS S.A.
Recruiting - verified February 2010
Rituximab, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Conditions: Drug/Agent Toxicity by Tissue/Organ; Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: carboplatin; Drug: cytarabine; Drug: mannitol; Drug: methotrexate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Conditions: Head and Neck Cancer; Radiation Toxicity
Interventions: Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
System Longevity Study: Monitoring Long-Term Function of Medtronic Heart-Related Products

Conditions: Arrhythmia; Bradycardia; Heart Failure; Sinus Tachycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Radiation Therapy in Treating Young Patients With Gliomas

Condition: Brain and Central Nervous System Tumors
Intervention: Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsor: Bristol-Myers Squibb
Available - verified January 2010
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

Conditions: Hepatitis C; Hepatitis C, Chronic
Interventions: Procedure: Continuous maintenance immunosuppressive therapy; Procedure: Immunosuppression withdrawal; Procedure: Liver transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified March 2010
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Condition: Head and Neck Cancer
Intervention: Drug: sorafenib tosylate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease

Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: epratuzumab; Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
BAY 43-9006 Plus Paclitaxel/Carboplatin in Women With GYN Tumors

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: sorafenib tosylate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Late-Occurring Complications in Childhood Cancer Survivors

Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Single-Fraction Radiation Therapy Compared With Multiple-Fraction Reirradiation Therapy in Treating Patients With Painful Bone Metastases

Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans Tasman Radiation Oncology Group at Calvary Mater Newcastle
Recruiting - verified March 2010
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Sodium Thiosulfate and Cytarabine in Treating Patients With Refractory or Recurrent Primary CNS Lymphoma

Conditions: Brain and Central Nervous System Tumors; Drug/Agent Toxicity by Tissue/Organ; Lymphoma; Thrombocytopenia
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: blood-brain barrier disruption chemotherapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: etoposide phosphate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: pentostatin
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: dexamethasone; Drug: melphalan; Drug: thalidomide; Procedure: peripheral blood stem cell transplantation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: umbilical cord blood transplantation; Drug: methylprednisolone
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Condition: Melanoma (Skin)
Intervention: Biological: PEG-interferon alfa-2b
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cyclophosphamide and Doxorubicin or Paclitaxel in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010

Find Paid Clinical Trials in Cleveland, Ohio - Clinical Trials

Find Paid Clinical Trials in Cleveland, Ohio

Paid Clinical Trials and Focus Groups by Location

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials